News

News Subscription

Jun 17. 2022
Cresemba® sales in Asia Pacific region trigger sales milestone payment to Basilea from Pfizer
Read more
Download
Apr 27. 2022
Basilea announces licensing of a novel first-in-class antifungal program from Fox Chase Chemical Diversity Center
Read more
Download
Apr 13. 2022
Basilea shareholders approve all proposals of the board of directors at the annual general meeting
Read more
Download
Apr 13. 2022
Basilea reports preclinical data on oncology drug candidates BAL0891, derazantinib and lisavanbulin at AACR Annual Meeting
Read more
Download
Mar 08. 2022
Basilea reports preclinical data on anti-cancer activity of novel oncology drug candidate BAL0891 at ESMO TAT congress
Read more
Download
Feb 15. 2022 / Ad hoc announcement
Basilea to become a leading anti-infectives company backed by strong financial results 2021
Read more
Download
Jan 24. 2022
Basilea reports updated interim results for iCCA patients with FGFR2 mutations and amplifications from phase 2 study FIDES-01 at ASCO GI Cancers Symposium
Read more
Download
Jan 13. 2022
Basilea announces approval of antifungal Cresemba® (isavuconazole) for invasive aspergillosis in China
Read more
Download
Jan 11. 2022
Basilea announces completion of patient enrolment in phase 3 ERADICATE study investigating ceftobiprole in bloodstream infections
Read more
Download
Jan 10. 2022 / Ad hoc announcement
Basilea exceeds 2021 financial guidance on preliminary revenue and year-end cash-position
Read more
Download